European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment–Update 2019; The mitogen-activated protein kinase pathway in melanoma part I–activation and primary resistance mechanisms to BRAF inhibition; Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma–results of a prospective biomarker study; Castration-resistant prostate cancer: mechanisms, targets, and treatment; Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study; MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition; S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma–short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of …; European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022; S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC)–short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up …; Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy; Time trends in incidence and mortality of cutaneous melanoma in Germany; Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients; MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma; Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR); The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration; Targeting tumor-resident mast cells for effective anti-melanoma immune responses; Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036; Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts; Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins; Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
